MAPT and Alzheimer disease: Interestingly, Selenica M-L et al. demonstrated in vivo that six different classes of small-molecules GSK3β inhibitors effectively inhibit tau phosphorylation in regions relevant to the pathogenesis of AD and at brain concentrations within their IC50 range [30].